Incyte Corp Unveils Promising Data on Hidradenitis Suppurativa at AAD 2026
Incyte Corporation (NASDAQ: INCY) has announced a significant advancement in its Inflammation and Autoimmunity (IAI) portfolio, as the company prepares to present late-breaking data from its pivotal research on hidradenitis suppurativa (HS) at the upcoming 2026 American Academy of Dermatology (AAD) Annual Meeting. This event will take place from March 27 to March 31, 2026, in Denver, Colorado.
1. Highlights of the Presentation
Dr. Jim Lee, Group Vice President for Inflammation and Autoimmunity at Incyte, emphasized the importance of the findings, stating, "At AAD 2026, we are presenting late-breaking 54-week results from the Phase 3 STOP-HS program evaluating povorcitinib in hidradenitis suppurativa (HS). These data provide longer-term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise."
The presentation will showcase crucial long-term data that could impact treatment options for patients suffering from HS, a painful and often debilitating skin condition characterized by inflamed lumps and abscesses.
Late-Breaking Oral Presentations
Incyte's focus on HS will be highlighted in an oral presentation titled:
- Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies
Session: S034 – Late-Breaking Research: Session 2
Date & Time: Saturday, March 28, 2026, at 1:00 p.m. MT
This presentation is expected to attract considerable attention from dermatology professionals and stakeholders, given the pressing need for effective treatments in the HS space.
ePoster Exhibits
In addition to the oral presentation, Incyte will also feature a range of ePoster exhibits that illustrate the breadth of its research portfolio. Key exhibits include:
Atopic Dermatitis
- Ruxolitinib Cream Improves Patient-Reported Outcomes in Adults With Moderate Atopic Dermatitis (TRuE-AD4) (Abstract #: 75312)
- Ruxolitinib Cream Is Efficacious in Adults With Moderate Atopic Dermatitis Regardless of Baseline Disease Severity and Previous Medication History (Abstract #: 70667)
Hidradenitis Suppurativa
- Povorcitinib for Moderate-to-Severe Hidradenitis Suppurativa: Week 24 Interim Phase 3 Results in Anti-TNF-Experienced Patients (Abstract #: 75195)
- Physician Perspectives on Diagnosis and Treatment of Hidradenitis Suppurativa: Results From the Global HERALD Survey (Abstract #: 75265)
- Disease Burden and Treatment History of Hidradenitis Suppurativa: Patient Perspectives From the Global HERALD Survey (Abstract #: 75268)
Vitiligo
- Association Between Repigmentation and Quality of Life Among Patients With Vitiligo Treated With Ruxolitinib Cream in the TRuE-V Studies (Abstract #: 75247)
- Real-World Factors Influencing Vitiligo Care: Insights From a Patient Survey Assessing the Use of Ruxolitinib Cream (Abstract #: 75258)
2. About Povorcitinib
Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently undergoing Phase 3 trials for hidradenitis suppurativa, vitiligo, and prurigo nodularis, as well as a Phase 2 trial for asthma. The ongoing research could position povorcitinib as a frontline treatment option for patients grappling with these challenging conditions.
3. Incyte's Commitment to Innovation
Incyte has established itself as a leader in biopharmaceutical innovation, focusing on developing first-in-class and next-generation medicines across its key franchises: Hematology, Oncology, and Inflammation and Autoimmunity. The company’s commitment to scientific expertise and patient-centric solutions is reflected in its diverse pipeline aimed at addressing unmet medical needs.
In conclusion, as Incyte prepares for the AAD Annual Meeting, the unveiling of late-breaking data on povorcitinib could mark a pivotal moment in the treatment landscape for hidradenitis suppurativa, potentially enhancing patient outcomes and solidifying Incyte's position in the inflammation and autoimmunity market. Investors and healthcare professionals alike will be closely monitoring the developments emerging from this prestigious gathering.
